MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.38
+0.08
+1.41%
Closed 16:00 11/14 EST
OPEN
5.31
PREV CLOSE
5.31
HIGH
5.42
LOW
5.21
VOLUME
508.24K
TURNOVER
--
52 WEEK HIGH
19.75
52 WEEK LOW
5.28
MARKET CAP
244.44M
P/E (TTM)
-2.4581
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CTMX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CTMX News

  • SunTrust sees 16% upside in Amgen in premarket analyst action
  • Seeking Alpha - Article.2d ago
  • Wedbush Downgrades CytomX Due To Lack Of Clarity On Development Paths
  • Benzinga.3d ago
  • Wedbush Downgrades CytomX Due To Lack Of Clarity On Development Paths
  • Benzinga.3d ago
  • Benzinga's Top Upgrades, Downgrades For November 11, 2019
  • Benzinga.3d ago

More

Industry

Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
-0.27%

Hot Stocks

Name
Price
%Change

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
More

Webull offers CytomX Therapeutics Inc (CTMX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.